LL-37: The Body's Own Antibiotic — What the Evidence Actually Shows
LL-37 is the human cathelicidin peptide with rich antimicrobial and wound-healing biology, but solid human data exists only for topical wound use — and it's dual-edged.
By Research Rats Editorial TeamReviewed by Research Rats Editorial Team
Evidence profile
Assessed 2026-06-17The body's own cathelicidin, with exceptionally well-characterised antimicrobial, immune-modulating and wound-repair biology in vitro and in animals — but human evidence is limited to topical chronic-wound trials (the lead phase IIb missed its primary endpoint), there is no human data for the injected/systemic use discussed online, and the same peptide is implicated in psoriasis, rosacea and lupus.
Exceptionally well-characterised innate-immunity biology: membrane-permeabilising antimicrobial action, LPS neutralisation and FPR2-mediated immune modulation, plus a documented pro-inflammatory/autoimmune-driving side.
A large, internally consistent in-vitro and animal body of work — though it is explicitly double-edged (both pro- and anti-inflammatory, context-dependent in cancer).
Limited to topical chronic-wound trials: the phase IIb HEAL LL-37 RCT (n=148) missed its primary endpoint (subgroup signal only), and a diabetic-foot-ulcer RCT moved granulation but not cytokines or bacterial load. No human data for injected/systemic use.
Even where best studied, the flagship topical trial missed its primary endpoint; in-vitro antimicrobial activity does not establish clinical treatment utility.
Human safety exists only for short-term topical use; the injected/systemic route discussed online has no human safety data, and the biology raises plausible pro-inflammatory/autoimmune (psoriasis, rosacea, lupus) and context-dependent cytotoxicity concerns.
The most advanced (topical) candidate reached phase IIb and then stalled, reportedly for financial reasons rather than on the science.
Moderate for the mechanism and the topical picture; low for the systemic/injected use that is most discussed.
No approved LL-37 product anywhere; the realistic injectable supply is unregulated research-grade peptide. FDA Category 2 nomination later withdrawn — not currently in the active Category 2 table, which is not a clearance and leaves the concerns FDA published standing.
Bars show the state of evidence, not desirability. A strong rating on any axis does not mean a compound is safe, effective, or recommended. Human evidence is often limited. Not medical advice.
What to know before reading further
Free for everyone — safety, evidence and regulatory context are never members-only.
Evidence context
The body's own cathelicidin, with exceptionally well-characterised antimicrobial, immune-modulating and wound-repair biology in vitro and in animals — but human evidence is limited to topical chronic-wound trials (the lead phase IIb missed its primary endpoint), with no human data for injected/systemic use.
Safety snapshot
Human safety exists only for short-term topical use; the injected route discussed online has no human safety data, and the same peptide is implicated in psoriasis, rosacea and lupus, so it can be pro-inflammatory and autoimmune-driving.
Regulatory & legality
No approved LL-37 product exists anywhere; the realistic injectable supply is unregulated research-grade peptide. The FDA lists it as Cathelicidin LL-37 among bulk substances nominated to Category 2 whose nominations were withdrawn, so it is not currently in the active Category 2 table; a withdrawal is not approval or clearance and the FDA still publishes the concerns it identified — including nonclinical findings suggesting detrimental effects on male reproduction and pro-tumorigenic effects in some tissues.
Where claims can exceed the evidence
In-vitro antimicrobial activity does not establish clinical treatment utility, and the 'natural antibiotic' framing overstates a context-dependent, double-edged molecule.
This article does not provide dosing, protocol, administration, sourcing, stack, or self-experimentation guidance, or personalised medical advice. It is educational and non-prescriptive — the evidence profile describes the state of research, not an individual decision.
Overview
LL-37 is the only antimicrobial peptide your body makes from the cathelicidin family — a 37-residue fragment cut from a precursor protein called hCAP-18, encoded by the CAMP gene [1]. It sits at the crossroads of innate immunity: it punches holes in microbes, recruits and tunes immune cells, and helps skin and blood vessels repair themselves [1][2][3]. On paper, it reads like a wonder molecule.
The reality is more nuanced, and worth being honest about. LL-37's mechanistic and preclinical biology is exceptionally well characterised, but the rigorous human evidence is narrow: it covers topical application to chronic wounds, and even the best trial missed its primary goal [5]. Just as importantly, LL-37 is genuinely double-edged — the same peptide that defends and repairs is overexpressed in psoriasis and helps drive autoimmune inflammation [10][11]. No LL-37 product is an approved drug anywhere, and there is no human evidence at all for injected or systemic use. This article walks through what is actually known, where the gaps are, and why the gaps matter.
Disclaimer. For educational and research purposes only. Not medical advice. We do not sell peptides or compounds.
This detailed research report is available to members
Research Rats is an 18+ educational research platform. Member-only content provides structured evidence interpretation only. It is not medical advice, dosing guidance, protocol guidance, sourcing guidance, cycle design, stack design or treatment advice.
Free safety information remains available where possible.
To continue, create an account or log in and agree to the Terms of Website Use, Privacy Notice, Cookie and Site Technologies Policy, and Medical, Health and Research Disclaimer.
Member access does not provide medical advice, dosing advice, sourcing advice, protocol guidance or treatment recommendations. How Research Rats works
[ Related research ]
ARA-290 (Cibinetide): The EPO-Derived Peptide That Targets Nerve Repair Without the Blood Risk
ARA-290 is an EPO-derived peptide with promising but unconfirmed Phase 2 signals in small fibre neuropathy. Mechanistically rational, consistently safe in short trials.
BPC-157: What the Evidence Actually Shows
A clear-eyed look at BPC-157: a peptide with promising rodent healing data, almost no human evidence, and serious regulatory and sourcing caveats.
KPV: The alpha-MSH Tripeptide With a Strong Preclinical Case and No Human Trials
KPV is an alpha-MSH-derived anti-inflammatory tripeptide with solid animal and cell-based evidence, mostly in gut inflammation, but zero published human trials.
TB-500 (Thymosin Beta-4): What the Evidence Actually Shows
TB-500's actin-repair biology is solid in animals, but human evidence exists only for topical eye drops — and injectable use rests on anecdote alone.